KR102330844B1 - Composition For Improving Sexual Function Containing 17 Herbal Ingredients And Schisandra Chinensis, Rubus Coreanus, Lycium Chinense, Torilis Japonica, And Cuscuta Australis - Google Patents
Composition For Improving Sexual Function Containing 17 Herbal Ingredients And Schisandra Chinensis, Rubus Coreanus, Lycium Chinense, Torilis Japonica, And Cuscuta Australis Download PDFInfo
- Publication number
- KR102330844B1 KR102330844B1 KR1020200181597A KR20200181597A KR102330844B1 KR 102330844 B1 KR102330844 B1 KR 102330844B1 KR 1020200181597 A KR1020200181597 A KR 1020200181597A KR 20200181597 A KR20200181597 A KR 20200181597A KR 102330844 B1 KR102330844 B1 KR 102330844B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- composition
- sexual function
- present
- fruit
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 74
- 230000036299 sexual function Effects 0.000 title claims abstract description 46
- 235000008422 Schisandra chinensis Nutrition 0.000 title claims abstract description 13
- 240000006079 Schisandra chinensis Species 0.000 title claims abstract description 13
- 239000004615 ingredient Substances 0.000 title abstract description 12
- 244000241872 Lycium chinense Species 0.000 title abstract description 3
- 235000015468 Lycium chinense Nutrition 0.000 title abstract description 3
- 241001618264 Rubus coreanus Species 0.000 title abstract description 3
- 244000013539 Cuscuta australis Species 0.000 title abstract 3
- 240000003803 Torilis japonica Species 0.000 title abstract 3
- 239000000284 extract Substances 0.000 claims abstract description 184
- 235000000421 Lepidium meyenii Nutrition 0.000 claims abstract description 25
- 240000000759 Lepidium meyenii Species 0.000 claims abstract description 25
- 235000012902 lepidium meyenii Nutrition 0.000 claims abstract description 25
- 241000383638 Allium nigrum Species 0.000 claims abstract description 23
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 23
- 235000012907 honey Nutrition 0.000 claims abstract description 23
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims abstract description 21
- 240000008397 Ganoderma lucidum Species 0.000 claims abstract description 21
- 235000006533 astragalus Nutrition 0.000 claims abstract description 17
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims description 21
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 17
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 17
- 241001061264 Astragalus Species 0.000 claims description 15
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 15
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 15
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 15
- 229940010454 licorice Drugs 0.000 claims description 15
- 210000004233 talus Anatomy 0.000 claims description 15
- 241000209020 Cornus Species 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 10
- 235000020687 goji berry extract Nutrition 0.000 claims description 9
- 239000006187 pill Substances 0.000 claims description 8
- 240000002045 Guettarda speciosa Species 0.000 claims description 7
- 240000007594 Oryza sativa Species 0.000 claims description 6
- 235000007164 Oryza sativa Nutrition 0.000 claims description 6
- 235000013376 functional food Nutrition 0.000 claims description 6
- 230000036541 health Effects 0.000 claims description 6
- 235000009566 rice Nutrition 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 3
- 239000006000 Garlic extract Substances 0.000 abstract description 5
- 235000020706 garlic extract Nutrition 0.000 abstract description 5
- 241000759833 Cornus officinalis Species 0.000 abstract description 4
- 235000018865 Angelica gigas Nutrition 0.000 abstract description 2
- 240000001810 Angelica gigas Species 0.000 abstract description 2
- 241000045403 Astragalus propinquus Species 0.000 abstract description 2
- 244000297531 Lespedeza cuneata Species 0.000 abstract description 2
- 241000405911 Rehmannia glutinosa Species 0.000 abstract description 2
- 244000237330 gutta percha tree Species 0.000 abstract description 2
- 240000008917 Glycyrrhiza uralensis Species 0.000 abstract 1
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 abstract 1
- 229940073700 hovenia dulcis fruit extract Drugs 0.000 abstract 1
- 229940074160 lycium chinense fruit extract Drugs 0.000 abstract 1
- 229940079990 rubus coreanus fruit extract Drugs 0.000 abstract 1
- 229940074091 schisandra chinensis fruit extract Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 33
- 239000002994 raw material Substances 0.000 description 32
- 230000006872 improvement Effects 0.000 description 21
- 230000000052 comparative effect Effects 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- 241000196324 Embryophyta Species 0.000 description 12
- 238000000605 extraction Methods 0.000 description 12
- 201000001881 impotence Diseases 0.000 description 12
- 230000001568 sexual effect Effects 0.000 description 12
- 239000003921 oil Substances 0.000 description 11
- 235000019198 oils Nutrition 0.000 description 11
- 235000015701 Artemisia arbuscula Nutrition 0.000 description 9
- 235000002657 Artemisia tridentata Nutrition 0.000 description 9
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 9
- 240000006891 Artemisia vulgaris Species 0.000 description 9
- 208000010228 Erectile Dysfunction Diseases 0.000 description 9
- 244000061520 Angelica archangelica Species 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 230000009986 erectile function Effects 0.000 description 7
- 230000037406 food intake Effects 0.000 description 7
- 230000036772 blood pressure Effects 0.000 description 6
- 229940069445 licorice extract Drugs 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000035946 sexual desire Effects 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 5
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 5
- 235000009685 Crataegus X maligna Nutrition 0.000 description 5
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 5
- 235000009486 Crataegus bullatus Nutrition 0.000 description 5
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 5
- 235000009682 Crataegus limnophila Nutrition 0.000 description 5
- 240000000171 Crataegus monogyna Species 0.000 description 5
- 235000004423 Crataegus monogyna Nutrition 0.000 description 5
- 235000002313 Crataegus paludosa Nutrition 0.000 description 5
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 241000283074 Equus asinus Species 0.000 description 5
- 244000241838 Lycium barbarum Species 0.000 description 5
- 240000008042 Zea mays Species 0.000 description 5
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 5
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 5
- 235000019206 astragalus extract Nutrition 0.000 description 5
- 235000005822 corn Nutrition 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 235000013336 milk Nutrition 0.000 description 5
- 239000008267 milk Substances 0.000 description 5
- 210000004080 milk Anatomy 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 230000018052 penile erection Effects 0.000 description 5
- 210000003899 penis Anatomy 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 235000005940 Centaurea cyanus Nutrition 0.000 description 4
- 240000004385 Centaurea cyanus Species 0.000 description 4
- 235000015459 Lycium barbarum Nutrition 0.000 description 4
- 201000001880 Sexual dysfunction Diseases 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 230000035790 physiological processes and functions Effects 0.000 description 4
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 231100000872 sexual dysfunction Toxicity 0.000 description 4
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 240000002234 Allium sativum Species 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 239000004129 EU approved improving agent Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 240000004371 Panax ginseng Species 0.000 description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000001856 erectile effect Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 235000004611 garlic Nutrition 0.000 description 3
- 235000008434 ginseng Nutrition 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 241000218922 Magnoliophyta Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 206010052004 Organic erectile dysfunction Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 235000004789 Rosa xanthina Nutrition 0.000 description 2
- 241000220222 Rosaceae Species 0.000 description 2
- ZFAHNWWNDFHPOH-YFKPBYRVSA-N S-allylcysteine Chemical compound OC(=O)[C@@H](N)CSCC=C ZFAHNWWNDFHPOH-YFKPBYRVSA-N 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000020710 ginseng extract Nutrition 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 230000007383 nerve stimulation Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229940124595 oriental medicine Drugs 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 230000001107 psychogenic effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 229940060595 sildenafil 20 mg Drugs 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 229940030961 sorghum extract Drugs 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- DSCFFEYYQKSRSV-UHFFFAOYSA-N 1L-O1-methyl-muco-inositol Natural products COC1C(O)C(O)C(O)C(O)C1O DSCFFEYYQKSRSV-UHFFFAOYSA-N 0.000 description 1
- JDLKFOPOAOFWQN-VIFPVBQESA-N Allicin Natural products C=CCS[S@](=O)CC=C JDLKFOPOAOFWQN-VIFPVBQESA-N 0.000 description 1
- 241000554155 Andes Species 0.000 description 1
- 241000544270 Angelica acutiloba Species 0.000 description 1
- 241000208173 Apiaceae Species 0.000 description 1
- 241000256837 Apidae Species 0.000 description 1
- 241000205585 Aquilegia canadensis Species 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000219193 Brassicaceae Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 241000207782 Convolvulaceae Species 0.000 description 1
- 241000142975 Cornaceae Species 0.000 description 1
- 244000301850 Cupressus sempervirens Species 0.000 description 1
- VJXUJFAZXQOXMJ-UHFFFAOYSA-N D-1-O-Methyl-muco-inositol Natural products CC12C(OC)(C)OC(C)(C)C2CC(=O)C(C23OC2C(=O)O2)(C)C1CCC3(C)C2C=1C=COC=1 VJXUJFAZXQOXMJ-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- DSCFFEYYQKSRSV-KLJZZCKASA-N D-pinitol Chemical compound CO[C@@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@H]1O DSCFFEYYQKSRSV-KLJZZCKASA-N 0.000 description 1
- 101150049660 DRD2 gene Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 101100189582 Dictyostelium discoideum pdeD gene Proteins 0.000 description 1
- 108090000511 Dopamine D1 Receptors Proteins 0.000 description 1
- 206010013789 Dry throat Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000380130 Ehrharta erecta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 241000208686 Eucommiaceae Species 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 208000007984 Female Infertility Diseases 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 241000222336 Ganoderma Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 108010078321 Guanylate Cyclase Proteins 0.000 description 1
- 102000014469 Guanylate cyclase Human genes 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000405398 Hovenia Species 0.000 description 1
- 235000008586 Hovenia Nutrition 0.000 description 1
- 235000008584 Hovenia dulcis Nutrition 0.000 description 1
- 244000010000 Hovenia dulcis Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 235000003332 Ilex aquifolium Nutrition 0.000 description 1
- 235000002296 Ilex sandwicensis Nutrition 0.000 description 1
- 235000002294 Ilex volkensiana Nutrition 0.000 description 1
- 206010021928 Infertility female Diseases 0.000 description 1
- 241000522169 Lespedeza Species 0.000 description 1
- 241000234435 Lilium Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010057672 Male sexual dysfunction Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 235000009421 Myristica fragrans Nutrition 0.000 description 1
- 244000270834 Myristica fragrans Species 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 101150098694 PDE5A gene Proteins 0.000 description 1
- 206010056303 Painful erection Diseases 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 240000001462 Pleurotus ostreatus Species 0.000 description 1
- 235000001603 Pleurotus ostreatus Nutrition 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 241000219100 Rhamnaceae Species 0.000 description 1
- 240000008199 Rhododendron molle Species 0.000 description 1
- 241000220221 Rosales Species 0.000 description 1
- ZFAHNWWNDFHPOH-UHFFFAOYSA-N S-Allyl-L-cystein Natural products OC(=O)C(N)CSCC=C ZFAHNWWNDFHPOH-UHFFFAOYSA-N 0.000 description 1
- 240000003829 Sorghum propinquum Species 0.000 description 1
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 241000365348 Trifolieae Species 0.000 description 1
- 102000011016 Type 5 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 1
- 108010037581 Type 5 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- JDLKFOPOAOFWQN-UHFFFAOYSA-N allicin Chemical compound C=CCSS(=O)CC=C JDLKFOPOAOFWQN-UHFFFAOYSA-N 0.000 description 1
- 235000010081 allicin Nutrition 0.000 description 1
- 102000004305 alpha Adrenergic Receptors Human genes 0.000 description 1
- 108090000861 alpha Adrenergic Receptors Proteins 0.000 description 1
- 239000001180 angelica archangelica l. root extract Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- CXWQXGNFZLHLHQ-DPFCLETOSA-N apomorphine hydrochloride Chemical compound [H+].[H+].O.[Cl-].[Cl-].C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3.C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 CXWQXGNFZLHLHQ-DPFCLETOSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 102100029175 cGMP-specific 3',5'-cyclic phosphodiesterase Human genes 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 229940015688 caverject Drugs 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940117229 cialis Drugs 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000005226 corpus cavernosum Anatomy 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000005225 erectile tissue Anatomy 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000749 insecticidal effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940097443 levitra Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 229940028444 muse Drugs 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000001702 nutmeg Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 206010036596 premature ejaculation Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 201000011264 priapism Diseases 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 239000009536 samultang Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 229960003310 sildenafil Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000007103 stamina Effects 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- WOXKDUGGOYFFRN-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C(C4=CC=CC=C4N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 WOXKDUGGOYFFRN-IIBYNOLFSA-N 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 229940126672 traditional medicines Drugs 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 229940094720 viagra Drugs 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
- A23L5/20—Removal of unwanted matter, e.g. deodorisation or detoxification
- A23L5/23—Removal of unwanted matter, e.g. deodorisation or detoxification by extraction with solvents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
- A23P10/28—Tabletting; Making food bars by compression of a dry powdered mixture
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/31—Foods, ingredients or supplements having a functional effect on health having an effect on comfort perception and well-being
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 17가지 한방 성분 및 오자를 포함하는 성기능 개선용 조성물에 관한 것으로, 구체적으로는 구기자 추출물, 토사자 추출물, 복분자 추출물, 사상자 추출물 및 오미자 추출물을 포함하는 제1 추출물; 및 야관문 추출물, 마카 추출물, 두충 추출물, 영지버섯 추출물, 흑마늘 추출물, 당귀 추출물, 감초 추출물, 황기 추출물, 꿀 추출물, 숙지황 추출물, 산수유 추출물 및 헛개나무열매 추출물을 포함하는 제2 추출물;을 포함하는 성기능 개선용 조성물에 관한 것이다.The present invention relates to a composition for improving sexual function comprising 17 kinds of oriental herbal ingredients and oja, specifically, a first extract comprising Goji berry extract, Tosaja extract, Bokbunja extract, Sasangsaeng extract and Schisandra extract; and a second extract comprising a sagebrush extract, a maca extract, a duchung extract, a reishi mushroom extract, a black garlic extract, an angelica extract, a licorice extract, an astragalus extract, a honey extract, a sorghum extract, a cornus extract, and an extract from sagebrush; It relates to a composition for improvement.
최근 통계에 따르면, 약 20 내지 60%의 성인 남성이 성기능 장애를 호소하고 있으며, 그 비율은 연령증가에 따라 증가하는 추세를 나타내고 있다. 이러한 성기능 장애는 과거에는 심인성(psychologic impotence) 원인으로 여겨졌으나, 의학의 발달로 인해 성기능 장애를 가진 환자의 약 50% 이상은 심인성 원인이 아닌 기질적 원인(organic impotence), 예를 들어 혈관계, 신경계 및 내분비계 질환, 당뇨병, 고혈압, 약물복용 등이 원인이 되는 것으로 밝혀지고 있다.According to recent statistics, about 20 to 60% of adult males complain of sexual dysfunction, and the proportion shows a tendency to increase with age. Such sexual dysfunction was considered to be a psychologic impotence cause in the past, but with advances in medicine, about 50% or more of patients with sexual dysfunction have an organic impotence rather than a psychogenic cause, for example, the vascular system, the nervous system. and endocrine system diseases, diabetes, hypertension, drug use, etc. have been found to be the cause.
남성의 성기능 장애는 크게 성행위에 필요한 발기력 및/또는 유지력 불능인 발기기능 장애와 사정 조절 능력의 상실로 야기되는 성신경과민증으로 나눌 수 있다.Male sexual dysfunction can be broadly divided into erectile dysfunction, which is the inability to maintain and/or erection necessary for sexual activity, and sexual sensitization caused by loss of ejaculation control ability.
상기 발기기능 장애란 일반적으로 발기부전증(발기 무능력), 지속발기증(음경이 지속적이고 고통스럽게 발기) 및 음경의 해면 조직과 관련 근막의 장애를 말한다. 상기 발기부전증은 심인성, 기질성 또는 이들의 복합적 요인에 의해 발생하며, 상기 기질성 발기 부전은 신경인성, 혈관성 및 내분비성 발기부전으로 분류한다. 이러한 성기능 저하는 인체의 생리기능의 저하와 밀접한 관계가 있으며 심할 경우 만성적인 발기부전으로 발전할 수 있다. 또한, 조루증으로 대표되는 성신경과민증은 말초신경계 및 중추신경계의 균형이 파괴되고 원활한 협조체제를 유지하지 못함으로 인해 성적조절 능력이 상실됨으로써 나타나는 증상으로 알려져 있다.The erectile dysfunction generally refers to erectile dysfunction (impotence of erection), priapism (permanent and painful erection of the penis), and disorders of the spongy tissue and related fascia of the penis. The erectile dysfunction is caused by psychogenic, organic, or a combination thereof, and the organic erectile dysfunction is classified into neurogenic, vascular and endocrine impotence. This decline in sexual function is closely related to the decline in physiological functions of the human body, and in severe cases, it can develop into chronic erectile dysfunction. In addition, sexual sensitization represented by premature ejaculation is known as a symptom that occurs due to the loss of sexual control ability due to disruption of the balance of the peripheral nervous system and the central nervous system and failure to maintain a smooth cooperative system.
종래에 성기능 관련한 제품은 화학물질을 사용한 발기부전 치료제 및 천연물을 사용한 제품으로 분류해 볼 수 있다.Conventionally, sexual function-related products can be classified into drugs for erectile dysfunction using chemical substances and products using natural products.
화학물질을 사용한 발기부전 치료제의 예로서 해면체의 확장을 방해하는 효소인 PDE5(Phosphodiesterase type-5) 저해제를 유효성분으로 포함하는 비아그라(Viagra), 레비트라(Levitra), 시알리스(Cialis) 등; 발기조직에 직접 작용하여 혈관을 확장시키는 PGE1(Prostaglandin E1)의 항진제를 유효성분으로 포함하는 카버젝트(Caverject), 뮤즈(Muse), 비파(Befar) 등; 도파민 D1/D2 수용체에 작용하는 유프리마(Uprima) 등이 있으며, 이들 외에도 α-아드레날린 수용체 길항제, 구아닐 싸이클라제(Guanylyl cyclase) 자극제, 세로토닌(5-hydroxytryptamine) 수용체 항진제 등이 개발되어 있다.Examples of the treatment for erectile dysfunction using chemicals include Viagra, Levitra, Cialis, and the like, which include PDE5 (Phosphodiesterase type-5) inhibitors, which are enzymes that interfere with the expansion of the cavernous body, as an active ingredient; Caverject, Muse, Befar, etc. containing an agonist of PGE1 (Prostaglandin E1), which acts directly on erectile tissue to dilate blood vessels, as an active ingredient; Uprima, which acts on dopamine D1/D2 receptors, etc., in addition to these, α-adrenergic receptor antagonists, guanylyl cyclase stimulants, and serotonin (5-hydroxytryptamine) receptor agonists have been developed.
또한, 천연물을 사용한 성기능 개선제들도 개발되어 있다. 예를 들어, 한국공개특허 제10-2002-0071326호에는 홍삼 엑기스 분말, 월견유, 난황유, 밀납, 대두유 및 레시틴을 포함하는 발기부전 개선용 조성물 및 이를 함유하는 식품이 개시되어 있고, 한국등록특허 제10-0475647호에는 고삼추출물을 포함하는 성기능 장애 개선용 조성물이 개시되어 있다.In addition, sexual function improving agents using natural products have been developed. For example, Korean Patent Laid-Open No. 10-2002-0071326 discloses a composition for improving erectile dysfunction comprising red ginseng extract powder, moon kernel oil, egg yolk oil, beeswax, soybean oil and lecithin and a food containing the same, and a Korean registered patent No. 10-0475647 discloses a composition for improving sexual dysfunction comprising a ginseng extract.
이러한 종래의 성기능 개선제, 특히 발기부전 치료제는 즉각적인 발기효과를 나타내기 위해 개발된 제품으로 일시적 발기 효과는 얻을 수 있으나 인체의 정상적인 생리기능이 파괴되어 체력이 저하되거나 생명의 위협이 될 수 있는 등 부작용이 나타날 수 있다. 또한 천연물을 사용한 성기능 개선제들은 일시적인 효과에 지나지 않거나 절대적인 효과가 미비한 문제점이 있다.These conventional sexual function improving agents, especially erectile dysfunction drugs, are products developed to show an immediate erection effect, and although a temporary erection effect can be obtained, the normal physiological function of the human body is destroyed and there are side effects such as reduced physical strength or a threat to life. may appear. In addition, there is a problem that sexual function improving agents using natural products are only temporary or have insufficient absolute effects.
따라서 인체의 정상적인 생리기능을 활성화시켜 저하된 성기능을 궁극적으로 개선시킬 수 있으면서도 인체에 부작용이 발생하지 않는 성기능 개선용 조성물의 개발이 요구되고 있는 실정이다.Therefore, there is a need to develop a composition for improving sexual function that can ultimately improve the lowered sexual function by activating the normal physiological function of the human body and does not cause side effects to the human body.
본 발명은 구기자 추출물, 토사자 추출물, 복분자 추출물, 사상자 추출물 및 오미자 추출물을 포함하는 제1 추출물; 및 야관문 추출물, 마카 추출물, 두충 추출물, 영지버섯 추출물, 흑마늘 추출물, 당귀 추출물, 감초 추출물, 황기 추출물, 꿀 추출물, 숙지황 추출물, 산수유 추출물 및 헛개나무열매 추출물을 포함하는 제2 추출물;을 포함하는 성기능 개선용 조성물을 제공한다.The present invention relates to a first extract comprising Goji berry extract, Tosaja extract, Bokbunja extract, Sasangsaeng extract and Schisandra extract; and a second extract comprising a sagebrush extract, a maca extract, a duchung extract, a reishi mushroom extract, a black garlic extract, an angelica extract, a licorice extract, an astragalus extract, a honey extract, a sorghum extract, a cornus extract, and an extract from sagebrush; A composition for improvement is provided.
본 발명은 성기능 개선용 조성물을 포함하는 건강기능식품을 제공한다.The present invention provides a health functional food comprising a composition for improving sexual function.
이하 이를 구체적으로 설명한다. 본 발명에서 개시된 다양한 요소들의 모든 조합은 본 발명의 범주에 속한다. 또한 하기의 구체적인 서술에 의해 본 발명 범주가 제한된다고 볼 수 없다.Hereinafter, this will be described in detail. All combinations of the various elements disclosed herein are within the scope of the present invention. In addition, it cannot be seen that the scope of the present invention is limited by the following specific description.
본 발명은 구기자 추출물, 토사자 추출물, 복분자 추출물, 사상자 추출물 및 오미자 추출물을 포함하는 제1 추출물; 및The present invention relates to a first extract comprising Goji berry extract, Tosaja extract, Bokbunja extract, Sasangsaeng extract and Schisandra extract; and
야관문 추출물, 마카 추출물, 두충 추출물, 영지버섯 추출물, 흑마늘 추출물, 당귀 추출물, 감초 추출물, 황기 추출물, 꿀 추출물, 숙지황 추출물, 산수유 추출물 및 헛개나무열매 추출물을 포함하는 제2 추출물;을 포함하는 성기능 개선용 조성물을 제공한다.Sexual function improvement, including; a second extract comprising a sagebrush extract, maca extract, duchung extract, reishi mushroom extract, black garlic extract, angelica extract, licorice extract, astragalus extract, honey extract, Sukhumi hwang extract, cornflower extract, and sagebrush extract; A composition is provided.
본 발명에서 “구기자”는 구기자나무(Lycium chinense) 또는 영하구기자(L. barbarum)의 열매를 의미하며, 독성물질의 배출 또는 해독, 노화방지, 지방간 제거, 만성 간질환의 개선 효과가 있으며, 기침, 어지럼증 등에 대해서도 다양한 효능이 있는 것으로 알려져 있다.In the present invention, "Goji berry" means the fruit of Lycium chinense or L. barbarum, and has the effect of discharging or detoxifying toxic substances, preventing aging, removing fatty liver, and improving chronic liver disease, and coughing , dizziness, etc. are known to have various effects.
본 발명에서 “토사자(Cuscutae Semen)”는 메꽃과에 속하는 한해살이 덩굴성 식물인 새삼의 씨앗을 의미하며, 플라보노이드(Flavonoids)가 주요 생리활성성분으로 알려져 있다. 토사자는 간 보호, 항산화, 항노화, 항암, 생식기계 등에 대한 효과가 있다.In the present invention, “Cuscutae Semen” refers to the seeds of ginseng, an annual creeping plant belonging to the family Convolvulaceae, and flavonoids are known as major physiologically active ingredients. Tosaja has effects on liver protection, antioxidant, anti-aging, anti-cancer, and reproductive system.
본 발명에서 “복분자(Rubus coreanus)”는 장미과의 낙엽 관목인 복분자딸기 또는 그 열매를 의미하며, 생리활성 성분으로 유기당, 당류 및 적은 양의 비타민C가 포함되어 있는 것으로 알려져 있다. 복분자는 간 기능 감퇴로 인한 시력감퇴, 정력감퇴 등에 효능이 있다.In the present invention, "Rubus coreanus" refers to bokbunja strawberry, a deciduous shrub of the Rosaceae, or its fruit, and is known to contain organic sugars, saccharides, and small amounts of vitamin C as physiologically active ingredients. Bokbunja is effective for loss of vision and stamina due to decreased liver function.
본 발명에서 “사상자(orilis japonica)”는 뱀도랏 또는 뱀밥풀이라고 지칭되는 미나리과의 두해살이풀을 의미하며, 신장을 보강하고 정수를 풍부히 하며 풍습을 없애고 살충효과가 있으며, 남성의 생식기능, 여성의 불임 등에 사용하고 자궁냉증, 트르코모나스성 질염에 의한 심한 가려움증, 백대하, 피부소양증에 효과가 있는 것으로 알려져 있다. 본 발명의 실시예들에 따르면, 사상자 추출물은 사상자 열매 추출물일 수 있으나 이에 제한되는 것은 아니다.In the present invention, "dealer (orilis japonica)" refers to a biennial herb of the buttercup family called Bamdorat or Bambabweed, which strengthens the kidneys, enriches water, eliminates customs and has an insecticidal effect, male reproductive function, and female infertility. It is used for uterine coldness, severe itching caused by Trchomonas vaginitis, and it is known to be effective for dermatitis and pruritus of the skin. According to embodiments of the present invention, the casualty extract may be, but is not limited to, an extract from the bovine botanical extract.
본 발명에서 “오미자(Schisandra chinensis)”는 산골짜기 암반지대에서 서식하는 덩굴성 식물인 오미자나무의 열매를 의미하며, 혈류 개선, 고혈압, 뇌졸중, 심혈관 질환 예방, 면역력 개선, 당뇨병 예방, 간기능 개선, 원기 회복, 호흡기 질환 개선 등의 효능이 있다.In the present invention, “Schisandra chinensis” refers to the fruit of the Schisandra tree, which is a creeping plant that lives in the rocky areas of mountain valleys, and improves blood flow, hypertension, stroke, cardiovascular disease, immunity, diabetes prevention, and liver function improvement. , recovery, and improvement of respiratory diseases.
본 발명에서 “야관문(Lespedeza cuneata G. Don)은 비수리 또는 삼엽초라고도 지칭되는 콩과(Leguminosae) 싸리속(Lespedeza)에 속하는 여러해살이 식물을 의미하며, 민간에서는 기침, 천식 등 치료에 사용되어 왔다. 야관문에 포함된 생리활성 물질로는 피니톨(pinitol), 플라보노이드(flavoid), 페놀(phenol) 등이 있으며, 자유라디칼 소거능 및 항산화 활성이 있는 것으로 보고되고 있다. 본 발명의 실시예들에 따르면, 야관문 추출물은 야관문 잎 또는 줄기 추출물일 수 있으나 이에 제한되는 것은 아니다.In the present invention, "Lespedeza cuneata G. Don" refers to a perennial plant belonging to the genus Lespedeza of the leguminosae family, also referred to as bisusu or trifolieae, and has been used in folklore to treat cough, asthma, etc. . Physiologically active substances contained in Yagwanmun include pinitol, flavonoids, phenols, and the like, and are reported to have free radical scavenging and antioxidant activity. According to embodiments of the present invention, the extract of ginseng may be, but not limited to, leaf or stem extracts of ginseng.
본 발명에서 “마카(Lepidium meyenii Walpers)”는 주로 페루의 안데스 산맥 해발 4,000m 이상의 고지대에서 재배되는 십자화과(Brassicaceae)에 속하는 식물을 의미하며, 추위, 강풍, 가뭄 등 어려운 자연 환경에서 자라는 마카는 생명력이 매우 강하고, 탄수화물, 단백질, 지질, 비타민, 무기질, 섬유소 등이 함유되어 있어 영양가가 높고 알칼로이드, 스테로이드, 탄닌, 사포닌 등의 다양한 생리기능성 물질을 포함하고 있는 것으로 알려져 있다. 본 발명에서 마카 추출물은 마카 뿌리 추출물일 수 있으나 이에 제한되는 것은 아니다.In the present invention, "Maca (Lepidium meyenii Walpers)" refers to a plant belonging to the Brassicaceae that is mainly cultivated in the Andes Mountains of Peru at an altitude of 4,000 m or higher, and Maca growing in difficult natural environments such as cold, strong wind, and drought has vitality It is very strong and contains carbohydrates, proteins, lipids, vitamins, minerals, and fibres, so it has high nutritional value and is known to contain various physiologically functional substances such as alkaloids, steroids, tannins, and saponins. In the present invention, the maca extract may be a maca root extract, but is not limited thereto.
본 발명에서 “두충(Eucommia ulmoides)”은 두충나무과(Eucommiaceae)에 속하는 낙엽교목을 의미하며, 주요 약리작용으로는 혈관 평활근 확장에 의한 혈압 감소, 항노화작용 등이 있다. 또한, 부신피질 호르몬을 증강시키고 항염증 작용을 나타내며, 진정 진통작용과 신체 면역 기능을 조절하여 세포면역의 억제 및 증강작용을 나타낸다. 또한, 출혈시간 단축, 이뇨작용, 항알레르기 작용 및 자궁수축 작용이 있다. 본 발명에서 두충 추출물은 두충 수피에서 추출된 것일 수 있으나 이에 제한되는 것은 아니다.In the present invention, "Eucommia ulmoides" refers to a deciduous tree belonging to the Eucommiaceae family, and the main pharmacological actions include blood pressure reduction by vascular smooth muscle expansion, anti-aging action, and the like. In addition, it enhances the adrenocortical hormone and exhibits anti-inflammatory action, and suppresses and enhances cellular immunity by regulating the sedative analgesic action and immune function of the body. In addition, it has a shortening of bleeding time, a diuretic action, an antiallergic action and a uterine contraction action. In the present invention, the cephalothorax extract may be extracted from the bark, but is not limited thereto.
본 발명에서 "영지버섯(Ganoderma Luciderm)"은 불로초라고도 지칭되는 여름에 활엽수 뿌리에서 발생하여 자라는 버섯을 의미하며, 이뇨, 보간, 강장, 정신 안정, 관절염 및 기관지염에 효과가 있으며, 혈압강하, 고지혈증 개선, 혈당강하, 면역증강 및 항종양 효과도 보고되고 있다.In the present invention, "reishi mushroom (Ganoderma Luciderm)" refers to a mushroom that occurs and grows from the roots of a broad-leaved tree in summer, which is also referred to as an oyster mushroom, and is effective in diuresis, interpolation, tonicity, mental stability, arthritis and bronchitis, lowering blood pressure, hyperlipidemia Improvement, hypoglycemia, immune enhancement and anti-tumor effects have also been reported.
본 발명에서 "흑마늘"은 마늘을 발효숙성시킨 것으로 생마늘에서 알리신의 생성을 억제하고, 30 내지 40일 정도 숙성시켜 S-알릴시스테인이라는 물질로 전환된 검은색의 마늘을 의미한다. 흑마늘은 위궤양이나 위염 등의 위장장애를 저하시키고 잔존 취를 감소시킬 수 있으며, 생마늘 대비 폴리페놀 함량, 항산화 효과 등이 증가되는 것으로 알려져 있다.In the present invention, "black garlic" refers to black garlic converted into a substance called S-allyl cysteine by inhibiting the production of allicin in raw garlic and aging it for about 30 to 40 days as fermented and aged garlic. Black garlic is known to reduce gastrointestinal disorders such as gastric ulcer or gastritis and reduce residual odor, and to increase polyphenol content and antioxidant effect compared to raw garlic.
본 발명에서 “당귀”는 산황과(Umbelliferae)에 속하는 다년생 초본인 안젤리카 기가스(Angelica gigas Nakai), 안젤리카 시넨시스(A. sinensis DIELS), 안젤리카 아쿠틸로바(A. acutiloba KITAG.) 및 동속 근연식물의 뿌리를 건조한 것을 의미하며, 보혈화혈, 조경지통, 윤조활장의 효능을 가진다고 알려져 있다. 뿌리는 진정작용, 진경작용, 혈압내림작용 등이 있고, 뿌리정유의 수용액을 관절염에 쓰면 진통작용과 소염작용이 있다. 본 발명의 실시예들에 따르면, 당귀 추출물은 당귀 뿌리 추출물일 수 있으나 이에 제한되는 것은 아니다.In the present invention, “Angelica” refers to perennial herbs belonging to the Umbelliferae, Angelica gigas Nakai, A. sinensis DIELS, Angelica acutiloba KITAG., and related plants. It means the dried root of the plant, and it is known to have the effects of bohyeolhwahyeol, landscape pain, and lubrication. The root has sedative, antispasmodic, and blood pressure lowering effects, and an aqueous solution of root essential oil for arthritis has analgesic and anti-inflammatory effects. According to embodiments of the present invention, the Angelica root extract may be, but is not limited thereto.
본 발명에서 “감초(Glycyrrhiza glabra)”는 쌍떡잎식물 장미목 콩과의 여러해살이풀을 의미하며, 생리활성 성분으로 글리시리친(glycyrrhizin), 플라보노이드(flavonoid), 만니톨(mannitol) 등을 포함하며, 항염증, 항알레르기, 항균효과 등이 있는 것으로 알려져 있다. 본 발명의 실시예들에 따르면, 감초 추출물은 감초 뿌리 또는 줄기 추출물일 수 있으나 이에 제한되는 것은 아니다.In the present invention, "licorice (Glycyrrhiza glabra)" refers to a perennial grass of the family Rosaceae, a dicotyledonous plant, and contains glycyrrhizin, flavonoid, mannitol, etc. as physiologically active ingredients, and It is known to have anti-inflammatory, anti-allergic and antibacterial effects. According to embodiments of the present invention, the licorice extract may be a licorice root or stem extract, but is not limited thereto.
본 발명에서 "황기"는 한국·중국·일본에 분포하는 콩과(Legumninosae)의 다년생초본인 단너삼(Astragalus membranaceus BUNCE)의 뿌리를 의미하며, 생리활성 성분으로 자당, 글루쿠론산, 점액질, 아미노산, 콜린, 베타인, 엽산 등을 포함하고 있다. 독성과 부작용이 없다고 알려졌으며, 한국, 중국 및 아시아 각지의 전통 의약품으로 다양하게 활용되어 왔다.In the present invention, "Astragalus" refers to the root of Astragalus membranaceus BUNCE, a perennial herb of Legumninosae distributed in Korea, China, and Japan, and includes sucrose, glucuronic acid, mucilage, amino acids, It contains choline, betaine, and folic acid. It is known to have no toxicity and side effects, and has been used in various ways as traditional medicines in Korea, China and Asia.
본 발명에서 “꿀(honey)”는 꽃의 화밀 또는 당분이 함유된 분비물(식물의 수액을 먹는 곤충의 분비물), 또는 이 두 가지 모두로부터 생성되는 밀원을 꿀벌이 채집하여 벌통의 육각형 벌집에 저장한 식용의 달콤한 물질을 의미한다. 꽃의 종류와 채집 시기에 따라 차이는 있으나 일반적으로 꿀은 수분 17 내지 20%, 당 76 내지 80%, 소량의 아미노산, 폴렌(화분)과 밀랍, 산, 단백질, 무기질(칼슘, 마그네슘, 인, 칼륨)을 함유하고 있으며, 부작용 없이 인체에 완벽히 흡수되는 것으로 알려져 있다.In the present invention, “honey” refers to honeybees collecting nectar from flowers or secretions containing sugar (secrets from insects that eat plant sap), or both, and stored in the hexagonal honeycomb of the hive. An edible sweet substance. Although there are differences depending on the type of flower and the collection period, in general honey contains 17 to 20% moisture, 76 to 80% sugar, a small amount of amino acids, pollen (pollen), beeswax, acids, proteins, minerals (calcium, magnesium, phosphorus, Potassium), and is known to be completely absorbed into the human body without side effects.
본 발명에서 “숙지황”은 지황(Rehmannia glutinosa)의 뿌리를 쪄서 말린 한약재를 의미하며, 맛은 달면서도 쓴맛이 돌고 따뜻한 성질이 있어 혈을 보하고 정을 보충해서 허리와 무릎이 시리고 아픈 증상이나 월경이상, 어지럼증 등을 치료하고 머리를 검게 하는 효과가 있다. 사물탕의 주요 약재이며 각종 만성병 중 몸이 허약하여 나타나는 내열, 인후건조, 갈증 등의 증상에 사용되는 것으로 알려져 있다.In the present invention, “Sukjihwang” refers to a herbal medicine obtained by steaming and drying the root of Rehmannia glutinosa. It has a sweet and bitter taste and has a warm nature, so as to replenish the blood and replenish the essence, so that the lower back and knees suffer from soreness or menstruation. It is effective in treating abnormalities, dizziness, etc. and darkening the hair. It is the main medicinal product of Samultang and is known to be used for symptoms such as heat resistance, dry throat, and thirst, which are caused by weakness of the body among various chronic diseases.
본 발명에서 “산수유(Cornus officinalis)”는 층층나무과 식물인 산수유의 열매를 의미하며, 성질은 약간 따뜻하고 맛은 시고 떫으며 독이 없는 성질을 가지고 있다. 사포닌의 함량이 15% 이상 함유되어 있어 수렴효과가 우수하며 또한 유해산소 제거 효과도 우수하여 피부를 개선해 주는 효과를 갖는 것으로 알려져 있다. 본 발명의 실시예들에 따르면, 산수유 추출물은 산수유 열매 추출물일 수 있으나 이에 제한되는 것은 아니다.In the present invention, “cornus officinalis” refers to the fruit of cornus oil, which is a plant of the Dogwood family, and has a slightly warm property, sour and astringent taste, and non-toxic properties. The content of saponin is 15% or more, so it has an excellent astringent effect and is also known to have an effect of improving the skin by removing harmful oxygen. According to embodiments of the present invention, the cornus oil extract may be a cornus fruit extract, but is not limited thereto.
본 발명에서 “헛개나무(Hovenia dulcis)”는 볼게나무, 호리께나무 또는 지구자나무라고도 지칭되는 식물계의 피자식물문의 쌍자엽식물강의 갈매나무목(Rhamnales)의 갈매나무과(Rhamnaceae)의 헛개나무속(Hovenia)에 속하는 식물을 의미하며, 주독 해독 및 간 보호, 항산화, 혈당강하, 항종양, 혈압강하 등의 효능이 있는 것으로 알려져 있다. 본 발명의 실시예들에 따르면, 헛개나무 추출물은 헛개나무 열매 추출물일 수 있으나 이에 제한되는 것은 아니다.In the present invention, "Hovenia dulcis" is a genus of Hovenia of the Rhamnaceae of the Rhamnales of the angiosperm phylum of the angiosperm phylum, also referred to as bolge, holly, or serrata. It means a plant belonging to the family, and is known to have effects such as poison detoxification, liver protection, antioxidant, blood sugar lowering, antitumor, and blood pressure lowering. According to embodiments of the present invention, the Heotgae tree extract may be a Heotgae tree fruit extract, but is not limited thereto.
본 발명에서 “추출물”은 적절한 추출용매를 사용하여 추출한 결과물을 의미하며, 상기 추출물은 추출로 인해 수득되는 추출액, 추출액의 희석액 또는 농축액, 추출액을 건조하여 얻어지는 건조물, 이들의 조정제물 또는 정제물, 또는 분획물을 포함한다.In the present invention, "extract" means the result of extraction using an appropriate extraction solvent, and the extract is an extract obtained by extraction, a diluted or concentrated solution of the extract, a dried product obtained by drying the extract, a prepared or purified product thereof, or fractions.
본 발명에서 “제1 추출물” 또는 “제2 추출물”은 각각 상이한 특정 추출물들을 포함하는 추출물 군을 의미한다. 본 발명의 실시예들에 따르면, 제1 추출물은 구기자 추출물, 토사자 추출물, 복분자 추출물, 사상자 추출물 및 오미자 추출물을 포함하는 것이며, 제2 추출물은 야관문 추출물, 마카 추출물, 두충 추출물, 영지버섯 추출물, 흑마늘 추출물, 당귀 추출물, 감초 추출물, 황기 추출물, 꿀 추출물, 숙지황 추출물, 산수유 추출물 및 헛개나무 추출물을 포함하는 것일 수 있다.In the present invention, "first extract" or "second extract" means an extract group comprising different specific extracts, respectively. According to embodiments of the present invention, the first extract is to include Goji berry extract, Tosaja extract, bokbunja extract, casualty locust extract and Schisandra extract, and the second extract is Yagwanmun extract, maca extract, Duchong extract, Reishi mushroom extract, and black garlic. It may include extracts, Angelica extract, licorice extract, Astragalus extract, honey extract, Sukhumus extract, Cornus officinalis extract, and Heotgae tree extract.
본 발명에서 제1 추출물 및 제2 추출물은 원재료로부터 추출된 각각의 추출물을 사후적으로 혼합한 것일 수 있으며, 원재료를 혼합한 후 동시에 추출된 복합 추출물일 수 있다.In the present invention, the first extract and the second extract may be a post-mixing of each extract extracted from the raw materials, and may be a complex extract extracted simultaneously after mixing the raw materials.
본 발명에서 "사후적으로 혼합"은 각각의 원재료로부터 추출물을 먼저 수득한 후, 수득된 결과물을 특정 중량비에 따라 혼합하는 것을 의미한다. 수득된 결과물은 동결건조된 형태일 수 있으나 이에 제한되는 것은 아니다.In the present invention, "post-mixing" refers to first obtaining an extract from each raw material, and then mixing the obtained product according to a specific weight ratio. The obtained product may be in a lyophilized form, but is not limited thereto.
본 발명에서 “복합 추출물”은 각각의 추출물의 원재료를 동시에 혼합한 혼합물 상태에서 제조공정을 통해 추출한 추출물을 의미한다. In the present invention, “composite extract” refers to an extract extracted through a manufacturing process in a mixture state in which the raw materials of each extract are mixed at the same time.
본 발명의 실시예들에 따르면, 제1 추출물은 원재료인 구기자, 토사자, 복분자, 사상자 및 오미자로부터 추출된 각각의 추출물을 사후적으로 혼합한 것일 수 있다. 또한 본 발명의 실시예들에 따르면, 제1 추출물은 구기자 추출물, 토사자 추출물, 복분자 추출물, 사상자 추출물 및 오미자 추출물을 9:7:5:3:1의 중량비로 포함하는 것일 수 있다. 후술하는 실험예에서 확인한 바와 같이, 상기 중량비의 추출물을 포함하고 있는 제1 추출물은 제2 추출물과의 시너지 효과로 인해 우수한 성기능 개선 효과를 나타낸다.According to embodiments of the present invention, the first extract may be a post-mixing of each extract extracted from the raw materials gugija, tosaja, bokbunja, sasansa and omija. In addition, according to embodiments of the present invention, the first extract may include Goji berry extract, Tosaja extract, bokbunja extract, Sasangsaeng extract and Schisandra extract in a weight ratio of 9:7:5:3:1. As confirmed in the experimental examples to be described later, the first extract containing the extract in the weight ratio exhibits an excellent sexual function improvement effect due to the synergistic effect with the second extract.
본 발명의 실시예들에 따르면, 제2 추출물은 야관문, 마카, 두충, 영지버섯, 흑마늘, 당귀, 감초, 황기, 꿀, 숙지황, 산수유 및 헛개나무를 혼합한 형태의 원재료 혼합물로부터 추출된 복합 추출물일 수 있다. 후술하는 실시예에서 확인할 수 있는 바와 같이, 제2 추출물은 각각의 원재료 추출물을 사후적으로 혼합한 경우 대비 원재료 혼합물로부터 추출된 복합 추출물을 포함하는 조성물은 성기능 개선 효과가 상승하였다. 또한 원재료가 포함된 혼합물로부터 추출된 복합 추출물을 포함하는 조성물에서도 특정 중량비의 원재료 혼합물로부터 추출된 복합 추출물이 더 우수한 성기능 개선 효과를 가지는 것을 확인할 수 있었다. 특정 이론에 얽매이지 않고, 어느 하나 이상의 원재료로부터 추출된 성분이 다른 원재료의 식물 세포벽을 자극하여 활성성분의 유출을 높이는 시너지 작용에 의해 각각의 원재료에 포함된 활성성분이 더욱 용이하게 추출되는 것으로 여겨진다.According to the embodiments of the present invention, the second extract is a complex extract extracted from a mixture of raw materials in the form of a mixture of sagebrush, maca, duchung, reishi mushroom, black garlic, angelica, licorice, astragalus, honey, sukjihwang, cornus oil, and sagebrush. can be As can be seen in Examples to be described later, the composition including the complex extract extracted from the raw material mixture has increased sexual function improvement effect compared to the case where the second extract is post-mixed with each raw material extract. In addition, it was confirmed that the complex extract extracted from the raw material mixture of a specific weight ratio has a better sexual function improvement effect even in the composition including the complex extract extracted from the mixture containing the raw material. Without being bound by a particular theory, it is believed that the active ingredient contained in each raw material is more easily extracted by the synergistic action of ingredients extracted from one or more raw materials stimulating the plant cell wall of other raw materials to increase the outflow of active ingredients .
본 발명에서 제2 추출물이 원재료들의 혼합물로부터 추출되는 경우, 상기 원재료 혼합물은 야관문, 마카, 두충, 영지버섯, 흑마늘, 당귀, 감초, 황기, 꿀, 숙지황, 산수유 및 헛개나무열매를 1-2:1-2:1-2:1-2:1-2:1-2:1-2:1-2:1-2:1-2:1-2:1-2의 중량비로 포함하는 것일 수 있으며, 바람직하게는 1:2:1:1:1:1:2:2:1:1:2:1의 중량비로 포함하는 것일 수 있다.In the present invention, when the second extract is extracted from a mixture of raw materials, the raw material mixture is a mixture of Yagwanmun, Maca, Duchong, Reishi mushroom, Black garlic, Angelica, Licorice, Astragalus, Honey, Sukhumang, Cornus oil and Heotgae fruit 1-2: It may be included in a weight ratio of 1-2:1-2:1-2:1-2:1-2:1-2:1-2:1-2:1-2:1-2:1-2 and preferably in a weight ratio of 1:2:1:1:1:1:2:2:1:1:2:1.
본 발명에서 구기자, 토사자, 복분자, 사상자, 오미자, 야관문, 마카, 두충, 영지버섯, 흑마늘, 당귀, 감초, 황기, 꿀, 숙지황, 산수유 및 헛개나무열매는 자연에서 채취하거나 직접 재배한 것 또는 시판 중인 것을 제한없이 사용할 수 있으며, 추출에 사용되는 식물 부위는 꽃, 잎, 종자, 열매, 뿌리 및/또는 줄기일 수 있다.In the present invention, goji berry, tosaja, bokbunja, saengjae, omija, yagwanmun, maca, tofu, reishi mushroom, black garlic, angelica, licorice, astragalus, honey, suksukhwang, cornus oil, and heotgae tree fruit are those harvested from nature or directly grown or commercially available. What is being used can be used without limitation, and the plant parts used for extraction may be flowers, leaves, seeds, fruits, roots and/or stems.
본 발명의 추출물은 당업계에서 통상적으로 사용되는 추출방법을 통해 제조할 수 있다. 예를 들면, 열탕 추출, 열수 추출, 냉침 추출, 환류 냉각 추출, 초음파 추출, 고온가압 추출 등의 방법을 사용할 수 있다.The extract of the present invention can be prepared through an extraction method commonly used in the art. For example, methods such as hot water extraction, hot water extraction, cold extraction, reflux cooling extraction, ultrasonic extraction, and high-temperature pressure extraction may be used.
본 발명의 추출물 제조함에 있어서, 추출용매로 물; 메탄올, 에탄올, 프로필알코올, 부틸알코올 등의 탄소수 1 내지 4의 저급 알코올; 글리세린, 부틸렌글리콜, 프로필렌글리콜 등의 다가알코올; 클로로포름, 메틸아세테이트, 에틸아세테이트, 벤젠, 헥산, 디에틸에테르, 페트롤륨에테르, 디클로로메탄 등의 탄화수소계 용매; 또는 이들의 혼합 형태를 사용할 수 있으며, 바람직하게는 물을 추출용매로 사용할 수 있다. 본 발명의 실시예들에 따르면, 본 발명의 추출물은 추출용매로서 유기용매의 사용을 배제하고 물을 사용하여 유기용매로 인한 활성성분의 변성, 부가물질의 생성 또는 추출 후 잔류하는 인체에 유해한 유기용매로 인한 부작용 등을 최소화하였다.In the preparation of the extract of the present invention, water as an extraction solvent; lower alcohols having 1 to 4 carbon atoms, such as methanol, ethanol, propyl alcohol, and butyl alcohol; polyhydric alcohols such as glycerin, butylene glycol and propylene glycol; hydrocarbon solvents such as chloroform, methyl acetate, ethyl acetate, benzene, hexane, diethyl ether, petroleum ether and dichloromethane; Or a mixture thereof may be used, and preferably water may be used as an extraction solvent. According to the embodiments of the present invention, the extract of the present invention excludes the use of an organic solvent as an extraction solvent, and uses water to denaturate the active ingredient due to the organic solvent, generate additional substances, or residual organic harmful to the human body after extraction. Side effects caused by solvents were minimized.
본 발명의 조성물에 포함되는 제1 추출물 및 제2 추출물의 함량은 다양한 요인, 예를 들면, 사용 목적, 사용 기간, 제형의 종류, 투여 경로, 투여하고자 하는 부위의 상태 등을 고려하여 적절하게 결정할 수 있다. 본 발명의 실시예들에 따르면, 제1 추출물 및 제2 추출물은 1:1 또는 10:9의 중량비로 포함될 수 있으나 이에 제한되는 것은 아니다.The content of the first extract and the second extract included in the composition of the present invention may be appropriately determined in consideration of various factors, for example, purpose of use, period of use, type of formulation, route of administration, state of the site to be administered, etc. can According to embodiments of the present invention, the first extract and the second extract may be included in a weight ratio of 1:1 or 10:9, but is not limited thereto.
본 발명에서 “개선”은 성기능과 관련된, 예를 들면 증상 또는 진행의 정도를 감소, 지연, 완화 또는 억제시키는 모든 행위 뿐만 아니라 역전시키는 행위도 포함시키는 것으로 해석될 수 있다. 본 발명에 있어서 성기능 개선은 음경의 발기능, 절정능, 성욕, 성교만족감 및 성생활의 전반적 만족감으로 이루어진 군에서 선택되는 하나 이상을 개선시키는 것일 수 있다.In the present invention, “improvement” may be construed to include not only all acts of reducing, delaying, alleviating or suppressing the degree of symptoms or progression related to sexual function, but also acts of reversing. Sexual function improvement in the present invention may be to improve one or more selected from the group consisting of erectile function, climax, sexual desire, sexual satisfaction, and overall satisfaction of sex life.
본 발명에서 성기능 개선용 조성물은 제1 추출물 및 제2 추출물에 찹쌀을 더 포함하는 것일 수 있다. 본 발명에서 찹쌀은 성기능 개선 효과를 저하하지 않는 범위 내에서 포함되는 것이 바람직하며, 구체적으로 전체 조성물의 중량 대비 5 내지 10 중량%, 바람직하게는 5 중량%로 포함되는 것이 바람직하다. 본 발명의 실시예에 따르면, 성기능 개선용 조성물은 제1 추출물, 제2 추출물 및 찹쌀을 10:9:1의 중량비로 포함하는 것일 수 있다. 후술하는 실험예에 따르면, 상기 중량비로 제조된 환제를 성기능 개선 효과를 확인하기 위해 지원자들에게 섭취하도록 하였으며, 섭취 전후로 발기능, 절정능, 성욕, 성교만족감 및 성생활의 전반적 만족감이 모두 상승하여 본 발명의 조성물이 우수한 성기능 개선 효과가 있었음을 확인할 수 있었다.In the present invention, the composition for improving sexual function may further include glutinous rice in the first extract and the second extract. In the present invention, glutinous rice is preferably included within a range that does not reduce the sexual function improvement effect, and specifically, it is preferably included in an amount of 5 to 10% by weight, preferably 5% by weight, based on the weight of the total composition. According to an embodiment of the present invention, the composition for improving sexual function may include the first extract, the second extract, and glutinous rice in a weight ratio of 10:9:1. According to the experimental example to be described later, volunteers were allowed to ingest the pills prepared in the above weight ratio to confirm the effect of improving sexual function, and before and after intake, erectile function, climax, sexual desire, sexual satisfaction, and overall satisfaction of sexual life all increased. It was confirmed that the composition of the present invention had an excellent sexual function improvement effect.
본 발명의 성기능 개선용 조성물은 효능 증진을 위해 추가 성분을 더 포함할 수 있다. 예를 들어, 상기 추가 성분은 추출물의 효능을 상쇄시키거나 감소시키지 않는다면 제한이 없다.The composition for improving sexual function of the present invention may further include an additional component to enhance efficacy. For example, the additional ingredients are not limited as long as they do not counteract or reduce the efficacy of the extract.
본 발명의 다른 양태는 본 발명의 성기능 개선용 조성물을 포함하는 건강기능식품이다. 여기서 성기능 개선용 조성물에 대해서는 전술한 바와 같으며, 명세서 내 동일 내용의 과도한 반복을 피하기 위해 생략한다.Another aspect of the present invention is a health functional food comprising the composition for improving sexual function of the present invention. Here, the composition for improving sexual function is the same as described above, and is omitted to avoid excessive repetition of the same content in the specification.
본 발명에서 상기 건강기능식품은 분말, 과립, 정제, 캡슐, 시럽 또는 음료와 같은 형태로 제조될 수 있으며, 바람직하게는 환제 형태일 수 있다.In the present invention, the health functional food may be prepared in the form of powder, granule, tablet, capsule, syrup or beverage, preferably in the form of a pill.
본 발명에서 제1 추출물 및 제2 추출물의 제조방법은 하기의 단계를 포함한다.The method for preparing the first extract and the second extract in the present invention includes the following steps.
원재료에서 이물질을 제거 후 건조하는 단계;Drying after removing foreign substances from the raw material;
상기 건조된 원재료를 분쇄하는 단계;pulverizing the dried raw material;
상기 분쇄된 원재료를 100℃에서 30분간 증열로스팅하는 로스팅 단계;a roasting step of steam roasting the pulverized raw material at 100° C. for 30 minutes;
상기 로스팅된 원재료에 15배 부피의 물을 첨가하여 침지시키는 단계;immersing the roasted raw material by adding 15 times the volume of water;
상기 침지된 원재료를 80℃에서 가압하에 3시간 추출하는 단계;extracting the immersed raw material at 80° C. under pressure for 3 hours;
원심분리기를 사용하여 20분간 원심분리(8,000 rpm, 15℃)하는 단계;centrifugation (8,000 rpm, 15° C.) for 20 minutes using a centrifuge;
상기 원심분리된 추출물을 여과시켜 고체잔사를 제거하는 단계; 및filtering the centrifuged extract to remove solid residues; and
상기 여과물을 농축하는 단계.Concentrating the filtrate.
본 발명의 17가지의 한방성분을 포함하는 성기능 개선용 조성물은 성기능과 관련된 인체의 생리기능을 회복시키는 것으로 일시적인 성기능의 개선 효과뿐만 아니라 성기능을 궁극적으로 개선시킬 수 있는 효과가 있다.The composition for improving sexual function comprising 17 oriental herbal ingredients of the present invention restores the physiological function of the human body related to sexual function, and has an effect of not only temporarily improving sexual function but also ultimately improving sexual function.
또한 본 발명의 성기능 개선용 조성물은 발기능, 절정능, 성욕, 성교 만족감 및 전반적 만족감을 증가시킬 수 있다.In addition, the composition for improving sexual function of the present invention can increase erectile function, climax, sexual desire, sexual satisfaction and overall satisfaction.
또한 본 발명의 조성물은 천연 한방 원재료로부터 추출된 한방 성분을 포함하므로 종래 화학적 치료제들이 가지던 문제점, 즉, 인체에 대한 유해성을 가지지 않는다.In addition, since the composition of the present invention contains oriental medicine ingredients extracted from natural oriental medicine raw materials, it does not have the problems of conventional chemical therapeutic agents, that is, harmful to the human body.
이하 본 발명을 실시예에 의해 보다 상세하게 설명한다. 그러나 이들 실시예는 본 발명을 예시적으로 설명하기 위한 것으로, 본 발명의 범위가 이들 실시예에 의해 제한되는 것은 아니다. 또한, 본 명세서에서 특별히 정의되지 않은 용어들에 대해서는 본 발명이 속하는 기술 분야에서 통상적으로 사용되는 의미를 갖는 것으로 이해되어야 할 것이다.Hereinafter, the present invention will be described in more detail by way of Examples. However, these examples are for illustrative purposes only, and the scope of the present invention is not limited by these examples. In addition, it should be understood that terms not specifically defined in this specification have meanings commonly used in the technical field to which the present invention pertains.
제조예manufacturing example
(1) 제1 추출물의 제조(1) Preparation of the first extract
1) 구기자 추출물의 제조1) Preparation of Goji berry extract
건조된 구기자 100 g을 분쇄하여 세절한 후, 약 100℃에서 30분간 증열로스팅 처리(로스터: FEC006, Biotech, Korea)하였다. 이후 상기 로스팅된 구기자를 반응기에 담은 후 약 15배 부피의 물을 첨가하였다. 이후 침지된 시료에 반응기를 이용하여 80℃에서 가압하에 3시간 동안 추출한 후, 원심분리기(Supra 22K, Hanil, Korea)를 이용하여 20분간 원심분리(8,000 rpm, 15℃)하였으며, 이에 따라 분리된 추출물을 정성 여과지 No.2(제조사: Whatman)를 사용하여 여과하고 농축시킨 후 20℃에서 동결 건조하였다.100 g of dried goji berries were crushed and chopped, and then steam roasted at about 100° C. for 30 minutes (roaster: FEC006, Biotech, Korea). After putting the roasted goji berries in a reactor, about 15 times the volume of water was added. After that, the immersed sample was extracted for 3 hours at 80°C under pressure using a reactor, and then centrifuged (8,000 rpm, 15°C) for 20 minutes using a centrifuge (Supra 22K, Hanil, Korea). The extract was filtered using qualitative filter paper No. 2 (manufacturer: Whatman), concentrated, and then freeze-dried at 20°C.
2) 토사자, 복분자, 사상자 및 오미자 추출물의 제조2) Preparation of extracts from Tosaja, bokbunja, sasansa and omija extracts
원재료로서 토사자, 복분자, 사상자 열매 및 오미자를 사용한 것을 제외하고는 구기자 추출물을 제조한 방법과 실질적으로 동일한 방법을 통해 토사자 추출물, 복분자 추출물, 사상자 추출물 및 오미자 추출물을 제조하였다.Tosaja extract, bokbunja extract, Sasangjae extract, and Schisandra extract were prepared in substantially the same manner as in the preparation of Goji extract except that Tosaja, bokbunja, Sasangsa fruit and Schisandra were used as raw materials.
3) 제1 추출물의 제조3) Preparation of the first extract
상기 동결건조된 구기자 추출물, 토사자 추출물, 복분자 추출물, 사상자 추출물 및 오미자 추출물을 9:7:5:3:1의 중량비로 혼합하여 시료 1-1의 제1 추출물을 제조하였다.A first extract of Sample 1-1 was prepared by mixing the freeze-dried Goji berry extract, Tosaja extract, Bokbunja extract, Sasangsaeng extract and Schisandra extract in a weight ratio of 9:7:5:3:1.
(2) 제2 추출물의 제조(2) Preparation of the second extract
1) 시료 2-1의 제조1) Preparation of Sample 2-1
건조된 원재료 혼합물{야관문(잎), 마카(뿌리), 두충(수피), 영지버섯, 흑마늘, 당귀(뿌리), 감초(뿌리), 황기(뿌리), 꿀, 숙지황(뿌리), 산수유(열매) 및 헛개나무(열매)}를 1:2:1:1:1:1:2:2:1:1:2:1의 중량비로 포함}을 분쇄기를 통해 세절한 후, 분쇄된 원재료 혼합물 100 g을 약 100℃에서 30분간 증열로스팅 처리(로스터: FEC006, Biotech, Korea)하였다. 이후 상기 로스팅된 원재료 혼합물을 반응기에 담은 후 약 15배 부피의 물을 첨가하였다. 이후 침지된 시료에 반응기를 이용하여 80℃에서 가압하에 3시간 동안 추출한 후, 원심분리기(Supra 22K, Hanil, Korea)를 이용하여 20분간 원심분리(8,000 rpm, 15℃)하였으며, 이에 따라 분리된 추출물을 정성 여과지 No.2(제조사: Whatman)를 사용하여 여과하고 농축시킨 후 20℃에서 동결 건조하여 시료 2-1의 제2 추출물을 수득하였다.Dried raw material mixture {Yakwanmun (leaf), maca (root), Duchong (bark), Reishi mushroom, black garlic, Angelica (root), licorice (root), Astragalus (root), honey, Sukhumvitae (root), Cornus officinalis (fruit) ) and cypress (fruit)} in a weight ratio of 1:2:1:1:1:1:2:2:1:1:2:1} were minced through a grinder, and then the pulverized raw material mixture 100 g was subjected to steam roasting treatment at about 100° C. for 30 minutes (roaster: FEC006, Biotech, Korea). Thereafter, the roasted raw material mixture was put in a reactor, and then water was added by about 15 times the volume. After that, the immersed sample was extracted for 3 hours at 80°C under pressure using a reactor, and then centrifuged (8,000 rpm, 15°C) for 20 minutes using a centrifuge (Supra 22K, Hanil, Korea). The extract was filtered using qualitative filter paper No. 2 (manufacturer: Whatman), concentrated, and then freeze-dried at 20° C. to obtain a second extract of Sample 2-1.
2) 시료 2-2 내지 2-5의 제조2) Preparation of Samples 2-2 to 2-5
원재료 혼합물에 포함되는 야관문(잎), 마카(뿌리), 두충(수피), 영지버섯, 흑마늘, 당귀(뿌리), 감초(뿌리), 황기(뿌리), 꿀, 숙지황(뿌리), 산수유(열매) 및 헛개나무(열매)의 중량비를 하기 표에 기재된 바와 같이 변경한 것을 제외하고는 상기 시료 2-1과 실질적으로 동일한 방법을 통해 시료 2-2 내지 2-5의 제2 추출물을 제조하였다.Ingredients included in the mixture of raw material mixture include sagebrush (leaf), maca (root), nutmeg (bark), reishi mushroom, black garlic, angelica (root), licorice (root), astragalus (root), honey, sukhumang (root), cornflower oil (fruit) ) and the second extract of Samples 2-2 to 2-5 were prepared in substantially the same manner as in Sample 2-1, except that the weight ratio of the tree (fruit) was changed as described in the table below.
2-1sample
2-1
2-2sample
2-2
2-3sample
2-3
2-4sample
2-4
2-5sample
2-5
3) 시료 2-6의 제조3) Preparation of samples 2-6
야관문, 마카, 두충, 영지버섯, 흑마늘, 당귀, 감초, 황기, 숙지황, 산수유 및 헛개나무 각각의 추출물(꿀은 원재료 그대로 첨가)을 상기 시료 2-1과 실질적으로 동일한 방법을 통해 제조한 후, 야관문 추출물, 마카 추출물, 두충 추출물, 영지버섯 추출물, 흑마늘 추출물, 당귀 추출물, 감초 추출물, 황기 추출물, 꿀, 숙지황 추출물, 산수유 추출물 및 헛개나무 추출물을 1:1:1:1:1:1:1:1:1:1:1:1의 중량비로 혼합하여 시료 2-6을 제조하였다.After preparing each extract (honey is added as it is) from Yagwanmun, maca, duchung, reishi mushroom, black garlic, angelica, licorice, astragalus, sorghum yellow, cornflower oil, and honeysuckle (honey is added as it is) in substantially the same manner as in Sample 2-1, 1:1:1:1:1:1:1:1 of wild ginseng extract, maca extract, duchong extract, reishi mushroom extract, black garlic extract, angelica lily extract, licorice extract, astragalus extract, honey, sujihwang extract, cornflower extract, and chrysanthemum extract Samples 2-6 were prepared by mixing in a weight ratio of 1:1:1:1:1:1.
실시예 및 비교예Examples and Comparative Examples
상기 제조예에서 제조한 제1 추출물 및 제2 추출물을 하기 표 2에 따라 약 1:1의 중량비로 혼합하고, 상기 혼합물에 정제수를 가해 현탁하여 실시예 및 비교예의 조성물을 제조하였다.The compositions of Examples and Comparative Examples were prepared by mixing the first extract and the second extract prepared in Preparation Example in a weight ratio of about 1:1 according to Table 2 below, and adding purified water to the mixture and suspending it.
실험예 1. 성기능 개선효과 확인 1Experimental Example 1. Confirmation of sexual function improvement effect 1
본 발명의 성기능 개선용 조성물의 음경 발기촉진 및 유지 효과를 확인하기 위하여 인체의 음경 해면체와 구조 및 생리학적 발기기전이 유사하다고 알려진 250 내지 300 g의 스프라그 도우리(spraque-dowley, (주) 샘타코 BIO KOREA) 종 수컷 레트(rat)를 대상으로 하여 동물실험을 수행하였다.In order to confirm the effect of promoting and maintaining penis erection of the composition for improving sexual function of the present invention, 250 to 300 g of sprag-dowley (spraque-dowley, Co.) Animal experiments were performed on male rats of Samtaco BIO KOREA) species.
구체적으로 온도 22±2℃상대습도 50±10%, 명암사이클(07:00 점등, 19:00 소등) 조건에서 사육된 레트에 각각 실시예 1 내지 5의 조성물(20 mg/kg 및 100 mg/kg), 비교예 1 및 2의 조성물, 생리식염수(음성대조군), 및 실데나필(양성대조군)을 주사기 및 존대(sonde)를 이용하여 구강에 직접 투여하고 30 내지 40분 후 해면체 내압을 측정하였다.Specifically, the compositions of Examples 1 to 5 (20 mg / kg and 100 mg / kg), the compositions of Comparative Examples 1 and 2, physiological saline (negative control group), and sildenafil (positive control group) were administered directly into the oral cavity using a syringe and sonde, and the cavernous pressure was measured after 30 to 40 minutes.
레트에 우레탄을 복강 내 주사하여 전신마취 시킨 후, 음경 표피를 절개하여 음경해면체를 노출시키고, 복부를 정중절개하여 골반 내 전립성 외측의 골반신경절을 박리하여 골반신경 및 음경해면체 신경을 노출시켰다. 상기 박리된 음경해면체 신경에는 백금 전극을 연결 후 전기 자극기에 연결하였다. 또한, 전신혈압(mean arterial pressure, MAP) 측정을 위해 경동맥에 폴리에틸렌관을 삽입하였다.After intraperitoneal injection of urethane into the rat was given general anesthesia, the epidermis of the penis was incised to expose the cavernous body, and the pelvic ganglion was removed through a median incision in the abdomen to expose the pelvic nerve and the cavernous nerve. A platinum electrode was connected to the exfoliated corpus cavernosum nerve and then connected to an electrical stimulator. In addition, a polyethylene tube was inserted into the carotid artery to measure mean arterial pressure (MAP).
상기 음경해면체에 23 게이지 침을 유치하고 전기자극기를 통해 음경해면체 신경을 자극(10 Hz, 3 V, 5 ms, 1 min)하고 이에 따른 해면체 내압을 측정하여 최대 음경해면체 내압(intracavernosal pressure, ICP) 및 전신혈압(MAP)를 측정하고 ICP/MAP (최대음경발기력) 비율을 5분 동안 기록하고 최대값을 비교하였다.A 23-gauge needle is placed in the cavernous body, and the cavernosal nerve is stimulated through an electrical stimulator (10 Hz, 3 V, 5 ms, 1 min), and the resulting intracavernosal pressure is measured to determine the maximum intracavernosal pressure (ICP). And systemic blood pressure (MAP) was measured, and the ICP/MAP (maximum penile erection) ratio was recorded for 5 minutes and the maximum values were compared.
전신혈압 및 해면체 내압은 그레스 텔레펙터 RPS312RM 및 데이터 수집장치로 측정하였으며, 측정된 데이터는 데이터 분석 프로그램을 이용하여 분석하였다.Systemic blood pressure and cavernous pressure were measured with a Gres telefactor RPS312RM and a data collection device, and the measured data were analyzed using a data analysis program.
(1) 음경해면체 신경자극에 의한 음경발기 반응 평가(1) Evaluation of penile erection response by penile cavernous nerve stimulation
음경해면체 신경자극에 의한 음경발기 반응 평가는 ICP/MAP 비율을 각각의 군별로 비교하여 평가하였으며, 구체적인 결과는 하기 표 3에 나타내었다.The evaluation of penile erection response by penile cavernous nerve stimulation was evaluated by comparing the ICP/MAP ratio for each group, and the specific results are shown in Table 3 below.
상기 표에서 확인할 수 있는 바와 같이, 본 발명의 조성물을 포함하는 실시예 1 내지 5의 조성물을 투여한 군에서는 최대음경발기력(ICP/MAP)이 비교예 1 (5가지 한방 성분을 포함한 조성물 투여), 음성대조군(생리식염수 투여) 대비 높게 나타났으며, 양성대조군(실데나필 20 mg/kg 투여)과 대등한 최대음경발기력을 나타내어 본 발명의 17가지 한방성분을 포함하는 조성물이 우수한 성기능 개선효과를 나타낼 수 있다는 점을 확인하였다. 또한 실시예 2 및 비교예 1 대비 시 제2 추출물 제조에 있어서 각각의 추출물을 혼합한 경우보다 원재료들의 혼합물로부터 수득된 제2 추출물을 포함하는 조성물이 더욱 우수한 성기능 개선효과를 나타내는 것으로 확인되었다.As can be seen in the table above, in the group administered with the compositions of Examples 1 to 5 containing the composition of the present invention, the maximum penile erection (ICP / MAP) was Comparative Example 1 (administration of a composition containing five herbal ingredients) , was higher than that of the negative control group (administered with physiological saline), and the maximum penile erection was comparable to that of the positive control group (administered with sildenafil 20 mg/kg). It was confirmed that it is possible. In addition, it was confirmed that the composition containing the second extract obtained from the mixture of raw materials in the preparation of the second extract compared to Example 2 and Comparative Example 1 exhibited a more excellent sexual function improvement effect than when each extract was mixed.
특히, 실시예 1의 조성물(야관문, 마카, 두충, 영지버섯, 흑마늘, 당귀, 감초, 황기, 꿀, 숙지황, 산수유 및 헛개나무를 1:2:1:1:1:1:2:2:1:1:2:1의 중량비로 포함하는 원재료 혼합물로부터 추출한 제2 추출물을 포함)의 경우, 실시예 2 내지 5의 조성물 대비 더욱 우수한 최대음경발기력을 나타냈는데, 이는 본 발명의 조성물에 포함되는 제2 추출물이 특정 중량비를 가진 원재료 혼합물로부터 추출되는 경우, 상승 효과로 인해 더욱 우수한 성기능 개선 효과를 나타낼 수 있음을 의미한다.In particular, the composition of Example 1 (Yakwanmun, Maca, Duchong, Reishi mushroom, black garlic, Angelica, licorice, Astragalus, honey, Sukhumvitae, Cornus oil and Heotgae tree 1:2:1:1:1:1:2:2: In the case of the second extract extracted from the raw material mixture included in a weight ratio of 1:1:2:1), it exhibited better maximum penis erection power compared to the compositions of Examples 2 to 5, which is included in the composition of the present invention. When the second extract is extracted from a raw material mixture having a specific weight ratio, it means that a more excellent sexual function improvement effect can be exhibited due to a synergistic effect.
(2) 발기유지력 평가(2) Erection maintenance evaluation
발기유지력은 음경해면체 자극 1분 전부터 자극 후 안정화되는 5분까지의 해면체 내압/혈압(%) 그래프의 누적 면적(cumulative Area Uunder the Curve; AUC)을 통해 확인하였으며, 실험 결과는 평균±표준오차(mean±standard Error; S.E.)로 하기 표 4에 나타내었다.Erectile holding power was confirmed through the cumulative area under the curve (AUC) of the cavernous body pressure/blood pressure (%) graph from 1 minute before penile cavernous stimulation to 5 minutes after stimulation, and the experimental results are the mean ± standard error ( The mean±standard error (SE) is shown in Table 4 below.
상기 표에서 확인할 수 있는 바와 같이, 본 발명의 조성물을 포함하는 실시예 1 내지 5의 조성물을 투여한 군에서는 발기유지력이 비교예 1(5가지 한방 성분을 포함한 조성물 투여), 음성대조군(생리식염수 투여) 대비 높게 나타났으며, 양성대조군(실데나필 20 mg/kg 투여)과 대등하거나 더 향상된 발기유지력을 나타내어 본 발명의 17가지 한방성분을 포함하는 조성물이 우수한 성기능 개선효과를 나타낼 수 있다는 점을 확인하였다. 또한 실시예 2 및 비교예 1 대비 시 제2 추출물 제조에 있어서 각각의 추출물을 혼합한 경우보다 원재료들의 혼합물로부터 수득된 제2 추출물을 포함하는 조성물이 더욱 우수한 성기능 개선효과를 나타내는 것으로 확인되었다.As can be seen in the table above, in the group administered with the compositions of Examples 1 to 5 containing the composition of the present invention, erectile maintenance was compared to Comparative Example 1 (administration of a composition containing five oriental medicinal ingredients), a negative control group (physiological saline solution) administration), and showed the same or improved erection retention power compared to the positive control group (administered with sildenafil 20 mg/kg), confirming that the composition containing 17 herbal ingredients of the present invention can exhibit excellent sexual function improvement effect did. In addition, it was confirmed that the composition containing the second extract obtained from the mixture of raw materials in the preparation of the second extract compared to Example 2 and Comparative Example 1 exhibited a more excellent sexual function improvement effect than when each extract was mixed.
특히, 실시예 1의 조성물(야관문, 마카, 두충, 영지버섯, 흑마늘, 당귀, 감초, 황기, 꿀, 숙지황, 산수유 및 헛개나무를 1:2:1:1:1:1:2:2:1:1:2:1의 중량비로 포함하는 원재료 혼합물로부터 추출한 제2 추출물을 포함)의 경우, 실시예 2 내지 5의 조성물 대비 더욱 우수한 발기유지력을 나타냈는데, 이는 본 발명의 조성물에 포함되는 제2 추출물이 특정 중량비를 가진 원재료 혼합물로부터 추출되는 경우, 상승 효과로 인해 더욱 우수한 성기능 개선 효과를 나타낼 수 있음을 의미한다.In particular, the composition of Example 1 (Yakwanmun, Maca, Duchong, Reishi mushroom, black garlic, Angelica, licorice, Astragalus, honey, Sukhumvitae, Cornus oil and Heotgae tree 1:2:1:1:1:1:2:2: In the case of the second extract extracted from the raw material mixture included in a weight ratio of 1:1:2:1), it exhibited better erection retention compared to the compositions of Examples 2 to 5, which is the agent included in the composition of the present invention. 2 When the extract is extracted from a mixture of raw materials having a specific weight ratio, it means that a better sexual function improvement effect can be exhibited due to the synergistic effect.
실험예 2. 성기능 개선효과 확인 2Experimental Example 2. Confirmation of sexual function improvement effect 2
본 발명의 성기능 개선용 조성물이 성기능 개선 효과를 가지는지 여부를 확인하기 위해 최근 1년 이내에 건강검진에서 고혈압, 당뇨병, 간질환, 신장질환, 제반 정신질환 등의 기질적, 정신적 질환이 없으며, 성기능 저하의 자각 증세가 있는 30세 이상 60세 미만의 기혼 남성 20명의 지원자를 대상으로 본 발명의 조성물을 포함하는 환제를 8주 동안 3 g씩 1일 2회 섭취하도록 하였다. 본 실험에 있어서 환제는 약 50 중량 %의 시료 1-1, 약 45 중량%의 시료 2-1 및 약 5 중량%의 찹쌀을 혼합한 후, 통상의 환제 제조방법을 통해 제조하였다.In order to check whether the composition for improving sexual function of the present invention has an effect of improving sexual function, there is no organic or mental disease such as high blood pressure, diabetes, liver disease, kidney disease, mental disease, etc. Twenty married male volunteers between the ages of 30 and less than 60 with symptoms of deterioration were instructed to take a pill containing the composition of the present invention 3 g twice a day for 8 weeks. In this experiment, the pills were prepared by mixing about 50% by weight of sample 1-1, about 45% by weight of sample 2-1 and about 5% by weight of glutinous rice, and then using a conventional pill manufacturing method.
설문 조사는 섭취 전/후 각각 실시하였으며, 발기능 측정 설문은 Rosen 이 분류한 발기능(6개 질문), 절정능(2개 질문), 성적욕구(2개 질문), 성교 만족감(3개 질문) 및 전반적 성생활 만족감(2개 질문)의 5개 항목이었다.The survey was conducted before and after ingestion, respectively, and the erectile function measurement questionnaire classified by Rosen was erectile function (6 questions), climax (2 questions), sexual desire (2 questions), sexual satisfaction (3 questions). ) and overall sexual life satisfaction (2 questions).
각각의 문항에 대해 0 내지 5 점으로 표시하도록 하고, 점수를 합한 후 평균을 계산하였으며, 결과는 하기 표 5에 나타내었다.Each question was marked with a score of 0 to 5, and the average was calculated after adding up the scores, and the results are shown in Table 5 below.
± 2.122.7
± 2.1
± 0.45.4
± 0.4
± 0.47.6
± 0.4
± 0.36.8
± 0.3
± 0.28.1
± 0.2
±0.45.5
±0.4
±0.610.6
±0.6
±0.34.1
±0.3
±0.27.8
±0.2
표 5에서 확인할 수 있는 바와 같이, 지원자들은 본 발명의 조성물을 포함하는 환제 섭취 전/후에 있어서 발기능, 절정능, 성욕, 성교 만족감 및 성생활의 전반적 만족감이 증가하였다. 따라서 본 발명의 17가지 한방성분을 포함하는 조성물이 우수한 성기능 개선효과를 나타낼 수 있다는 점을 확인하였다As can be seen in Table 5, the volunteers increased erectile function, climax, sexual desire, sexual satisfaction, and overall satisfaction with sex life before and after ingestion of a pill containing the composition of the present invention. Therefore, it was confirmed that the composition comprising 17 kinds of oriental herbal ingredients of the present invention can exhibit excellent sexual function improvement effect.
또한, 지원자들 중 실험기간 내 환제의 투여와 관련된 특별한 부작용, 예를 들면 설사 등의 부작용은 보고되지 않아 본원발명의 조성물이 우수한 안정성을 가진다는 점을 확인하였다.In addition, it was confirmed that the composition of the present invention has excellent stability because no special side effects related to the administration of the pills, for example, diarrhea, etc. were reported among the volunteers during the experiment.
Claims (8)
야관문, 마카, 두충, 영지버섯, 흑마늘, 당귀, 감초, 황기, 꿀, 숙지황, 산수유 및 헛개나무열매를 1:2:1:1:1:1:2:2:1:1:2:1의 중량비로 혼합한 후에 100℃에서 30분간 열로스팅 하고 80℃에서 가압하에 3시간 동안 열수 추출하여 수득한 제2 추출물의 건조물;을 포함하는 성기능 개선용 조성물로서,
상기 조성물은 찹쌀을 더 포함하여 제1 추출물, 제2 추출물의 건조물 및 찹쌀을 10:9:1의 중량비로 포함하는 것인 성기능 개선용 조성물.A first extract comprising a dry matter of Goji berry extract, a dry matter of a Tosaja extract, a dry matter of a bokbunja extract, a dry matter of the Sasangsaeng extract, and a dry matter of the Schisandra extract in a weight ratio of 9:7:5:3:1; and
Yagwanmun, Maca, Duchong, Reishi mushroom, Black Garlic, Angelica, Licorice, Astragalus, Honey, Sulfuricaceae, Cornus oil, and Heotgae fruit 1:2:1:1:1:1:1:2:2:1:1:2:1 As a composition for improving sexual function, comprising: after mixing in a weight ratio of
The composition further includes glutinous rice, the first extract, the dry matter of the second extract, and glutinous rice in a weight ratio of 10:9:1 for improving sexual function.
상기 건강기능식품은 환제 형태인 성기능 개선용 건강기능식품.8. The method of claim 7,
The health functional food is a health functional food for improving sexual function in the form of pills.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200181597A KR102330844B1 (en) | 2020-12-23 | 2020-12-23 | Composition For Improving Sexual Function Containing 17 Herbal Ingredients And Schisandra Chinensis, Rubus Coreanus, Lycium Chinense, Torilis Japonica, And Cuscuta Australis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200181597A KR102330844B1 (en) | 2020-12-23 | 2020-12-23 | Composition For Improving Sexual Function Containing 17 Herbal Ingredients And Schisandra Chinensis, Rubus Coreanus, Lycium Chinense, Torilis Japonica, And Cuscuta Australis |
Publications (1)
Publication Number | Publication Date |
---|---|
KR102330844B1 true KR102330844B1 (en) | 2021-11-23 |
Family
ID=78694943
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020200181597A KR102330844B1 (en) | 2020-12-23 | 2020-12-23 | Composition For Improving Sexual Function Containing 17 Herbal Ingredients And Schisandra Chinensis, Rubus Coreanus, Lycium Chinense, Torilis Japonica, And Cuscuta Australis |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102330844B1 (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020071326A (en) | 2001-03-06 | 2002-09-12 | 팍스바이오젠 주식회사 | Composition for improving erectile dysfunction and foods containing the same |
KR20030035482A (en) * | 2001-10-31 | 2003-05-09 | 주식회사 케이티앤지 | Compositin of Korean Red Ginseng Including Oriental Herbs for Improving Sexual Function and Manufacturing Method the Same and Its Use |
KR100475647B1 (en) | 2002-05-15 | 2005-03-10 | 한국과학기술연구원 | A composition for treating sexual dysfunction comprising an extract from sophora flavescens and compounds isolated therefrom |
KR20100077781A (en) * | 2008-12-29 | 2010-07-08 | 정인학 | Method for preparing functional powder to improve erectile dysfunction and assistance food comprising the functional powder |
KR20160073542A (en) * | 2014-12-17 | 2016-06-27 | 홍상근 | Composition for improving sexual function, Functional food Composition for improving sexual function comprising of the same and Manufacturing method thereof |
-
2020
- 2020-12-23 KR KR1020200181597A patent/KR102330844B1/en active IP Right Grant
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020071326A (en) | 2001-03-06 | 2002-09-12 | 팍스바이오젠 주식회사 | Composition for improving erectile dysfunction and foods containing the same |
KR20030035482A (en) * | 2001-10-31 | 2003-05-09 | 주식회사 케이티앤지 | Compositin of Korean Red Ginseng Including Oriental Herbs for Improving Sexual Function and Manufacturing Method the Same and Its Use |
KR100475647B1 (en) | 2002-05-15 | 2005-03-10 | 한국과학기술연구원 | A composition for treating sexual dysfunction comprising an extract from sophora flavescens and compounds isolated therefrom |
KR20100077781A (en) * | 2008-12-29 | 2010-07-08 | 정인학 | Method for preparing functional powder to improve erectile dysfunction and assistance food comprising the functional powder |
KR20160073542A (en) * | 2014-12-17 | 2016-06-27 | 홍상근 | Composition for improving sexual function, Functional food Composition for improving sexual function comprising of the same and Manufacturing method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105582333A (en) | Okra wine capable of preserving health and tonifying kidneys and preparation method thereof | |
CN101612315A (en) | A kind of compound Chinese medicinal preparation that is used to adjust function of human body | |
KR20070118754A (en) | Pharmaceutical composition for treating or preventing diabetes mellitus containing an extract of chinese herb as an effective ingredient | |
US20200147166A1 (en) | Health supplement food for promotion of hair growth, mitigation and alleviation of hair loss, regulation of blood glucose, and alleviation and relief of gastric disorder symptoms | |
CN105454576A (en) | Jasmine-flower-comprising assorted Chinese herbal tea and preparation method thereof | |
KR101751211B1 (en) | Composition for improving sexual function, Functional food Composition for improving sexual function comprising of the same and Manufacturing method thereof | |
KR101947786B1 (en) | Food Composition for Stress Relaxation, Fatigue Recovery or Athletic Performance Enhancement Comprising Extract of herb | |
CN108813501B (en) | Health-preserving honey paste with functions of clearing heat, moistening lung, relieving cough, reducing phlegm, relieving asthma and regulating human body functions | |
KR101771090B1 (en) | Composition for body temperature rise with medicinal herbs classified as a food ingredient and Manufacturing method thereof | |
KR101788253B1 (en) | Composition for improving male sexual function comprising the extract of Alpinia Officinarum, Smilacina Japonica & Black Garlic | |
CN104223297B (en) | A kind of schisandra chinensis health-care oral liquid of slow down aging and preparation method thereof | |
KR102092509B1 (en) | Food composition for preventing and improving of dementia | |
KR20100077781A (en) | Method for preparing functional powder to improve erectile dysfunction and assistance food comprising the functional powder | |
KR102127411B1 (en) | Composition comprising natural complex extract for protecting liver and relieving hangover | |
CN109430854B (en) | Health product and preparation method thereof | |
CN110810693A (en) | A beverage composition containing Ampelopsis grossedentata and its preparation method | |
KR102330844B1 (en) | Composition For Improving Sexual Function Containing 17 Herbal Ingredients And Schisandra Chinensis, Rubus Coreanus, Lycium Chinense, Torilis Japonica, And Cuscuta Australis | |
KR101028073B1 (en) | Natural herb medicine composition improving blood circulation and immune activity of human body and its process of production | |
KR100850503B1 (en) | Composition for improving erectile dysfunction and erection maintenance containing the extract of crude drug complex | |
KR101822834B1 (en) | Composition for improving menopausal symptom | |
CN108813500B (en) | Health-preserving honey paste with effects of tonifying middle-jiao and Qi, nourishing blood and soothing nerves and regulating human body functions | |
CN112402569A (en) | Anti-fatigue health product and preparation method thereof | |
CN113180243A (en) | Ginseng and radix puerariae paste plant composition and preparation method thereof | |
Roy et al. | Herbs Used In Peptic Ulcer: A Review. | |
KR100955826B1 (en) | Pill type a Healthy Food for Improving and Alleviating Inflammatory disease and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GRNT | Written decision to grant |